SCHEMBL7553483

SCHEMBL7553483

COc1cccc(C(=CC2=NCCN2)c2ccc3ccccc3n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.55
MAPK10 P53779 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
NISCH Q9Y2I1 3/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39
HTR1B P28222 1/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
GAA P10253 2/20 0.37
MEN1 O00255 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7553482 1.00 CNR2 (0.55) CNR2MAPK10NPC1RAB9ASMN1; SMN2
SCHEMBL7550912 0.82 CNR2 (0.55) CNR2NISCHKDM4EALDH1A1CYP1A2
SCHEMBL7550909 0.82 CNR2 (0.55) CNR2NISCHKDM4EALDH1A1CYP1A2
SCHEMBL10400667 0.80 CNR2 (0.70) CNR2MAPK10NPC1RAB9ASMN1; SMN2
SCHEMBL10400668 0.80 CNR2 (0.70) CNR2MAPK10NPC1RAB9ASMN1; SMN2
SCHEMBL10400666 0.80 CNR2 (0.70) CNR2MAPK10NPC1RAB9ASMN1; SMN2
SCHEMBL7555175 0.79 NISCH (0.46) NPC1NISCHKDM4ECYP1A2CYP3A4
SCHEMBL7555168 0.79 NISCH (0.46) NPC1NISCHKDM4ECYP1A2CYP3A4
SCHEMBL7555183 0.79 NISCH (0.46) NPC1NISCHKDM4ECYP1A2CYP3A4
SCHEMBL7550137 0.79 NISCH (0.40) CNR2MAPK10NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US claimed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO claimed
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 CNR2 2676/4885MAPK10 2010/4885NPC1 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.